WO2007093603A1 - 1-phenethylpiperidine derivatives and their use as opioid receptor ligands - Google Patents

1-phenethylpiperidine derivatives and their use as opioid receptor ligands Download PDF

Info

Publication number
WO2007093603A1
WO2007093603A1 PCT/EP2007/051400 EP2007051400W WO2007093603A1 WO 2007093603 A1 WO2007093603 A1 WO 2007093603A1 EP 2007051400 W EP2007051400 W EP 2007051400W WO 2007093603 A1 WO2007093603 A1 WO 2007093603A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperidin
ylmethyl
propionamide
fluoro
Prior art date
Application number
PCT/EP2007/051400
Other languages
French (fr)
Inventor
Dan Peters
Birgitte L. Eriksen
Gordon Munro
Elsebet Østergaard NIELSEN
John Paul Redrobe
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to AT07726356T priority Critical patent/ATE466841T1/en
Priority to DE602007006280T priority patent/DE602007006280D1/en
Priority to US12/161,309 priority patent/US20100234427A1/en
Priority to CA002641913A priority patent/CA2641913A1/en
Priority to EP07726356A priority patent/EP1987001B1/en
Priority to JP2008554765A priority patent/JP2009526815A/en
Publication of WO2007093603A1 publication Critical patent/WO2007093603A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel 1-phenethylpiperidine derivatives useful as opioid receptor ligands. More specifically, the invention provides compounds useful as ⁇ opioid receptor ligands.
  • the invention relates to the use of these compounds in a method for therapy, such as for the treatment of pain, and to pharmaceutical compositions comprising the compounds of the invention.
  • opioid receptors Numerous classes of opioid receptors exist. These classes differ in their affinity for various opioid ligands and in their cellular and organ distribution. Moreover, although the different classes are believed to serve different physiological functions, there is a substantial overlap of function, as well as distribution. Three different types of opioid receptors have been identified, the mu ( ⁇ ), delta ( ⁇ ) and kappa (K) opioid receptor. These three opioid receptor types are the sites of action of opioid ligands producing analgesic effects. However, the type of pain inhibited and the secondary functions vary with each receptor type. The ⁇ receptor is generally regarded as primarily associated with pain relief, and drug or other chemical dependence, such as addiction or alcoholism. The ⁇ receptor appears to deal with behavioural effects, although the ⁇ and the K receptors may also mediate analgesia.
  • Each opioid receptor when coupled with an opiate, causes a specific biological response unique to that type of receptor.
  • an opiate activates more than one receptor, the biological response for each receptor is affected, thereby producing side effects.
  • morphine which is a strong opioid analgetic agent shows effectiveness against strong pain by acting on the ⁇ opioid receptor (agonist activity)
  • side effects such as nausea and neurologic manifestation including hallucination and derangement.
  • morphine forms psychological dependence, causing serious problems.
  • Other side effects reported are respiratory depression, tolerance, physical dependence capacity, and precipitated withdrawal syndrome, caused by non-specific interactions with central nervous receptors.
  • WO 03/004026 describes substituted 1-phenethylpiperidine compounds used as inter alia analgesics.
  • a further object of the invention is the provision of compounds that substantially avoid the unwanted side effects associated with conventional peripherally acting analgesics.
  • a still further object is the provision of compounds that in addition show activity as monoamine neurotransmitter re-uptake inhibitors.
  • the invention provides a compound of Formula I,
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, any of 0 its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides the use of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the 5 treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the opioid receptor.
  • the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal 0 body, including a human, which disorder, disease or condition is responsive to responsive to modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
  • the invention provides a compound of Formula I,
  • the invention provides a compound of Formula II,
  • R a represents hydrogen, alkyl or R d ; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and R b , R c and R d independent of each other represent an aryl group; which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl
  • n is 1. In a second embodiment, n is 2.
  • R a represents alkyl. In a special embodiment, R a represents methyl or ethyl.
  • R b represents an optionally substituted aryl group, such as an optionally substituted phenyl.
  • R b represents phenyl.
  • R b represents halophenyl, such as fluorophenyl, chlorophenyl, 4-halophenyl or 3-halophenyl, in particular 4-chlorophenyl, 4-fluorophenyl or 3-fluorophenyl.
  • R b represents alkoxyphenyl, such as 4-alkoxyphenyl, 3-alkoxyphenyl or methoxyphenyl, in particular 4-methoxyphenyl or 3-methoxyphenyl.
  • R b represents phenyl substituted with methylenedioxy, such as benzo[1 ,3]dioxol-5-yl.
  • R b represents -CH 2 -R 6 .
  • R b represents benzyl.
  • R c represents an optionally substituted aryl group.
  • R c represents phenyl.
  • R c represents halophenyl, such as fluorophenyl, chlorophenyl, A- halophenyl or 3-halophenyl, in particular 4-chlorophenyl, 4-fluorophenyl or 3- fluorophenyl.
  • R c represents alkoxyphenyl, such as A- alkoxyphenyl or methoxyphenyl, in particular 4-methoxyphenyl.
  • R f represents phenyl.
  • R c represents
  • halo represents fluoro, chloro, bromo or iodo.
  • an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain.
  • the hydrocarbon chain preferably contains of from one to six carbon atoms (Ci- 6 -alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl.
  • alkyl represents a Ci- 4 -alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl.
  • alkyl represents a Ci- 3 -alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
  • an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes.
  • the alkenyl group of the invention comprises of from two to six carbon atoms (C 2 - 6 -alkenyl), including at least one double bond.
  • the alkenyl group of the invention is ethenyl; 1 - or 2-propenyl; 1 -, 2- or 3- butenyl, or 1 ,3-butadienyl; 1 -, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexadienyl, or 1 ,3,5- hexatrienyl.
  • an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes.
  • the alkynyl group of the invention comprises of from two to six carbon atoms (C 2 - 6 -alkynyl), including at least one triple bond.
  • the alkynyl group of the invention is ethynyl; 1 -, or 2-propynyl; 1 -, 2-, or 3- butynyl, or 1 ,3-butadiynyl; 1 -, 2-, 3-, 4-pentynyl, or 1 ,3-pentadiynyl; 1 -, 2-, 3-, A-, or 5- hexynyl, or 1 ,3-hexadiynyl or 1 ,3,5-hexatriynyl.
  • a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C 3-7 -cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Alkoxy is -O-alkyl, wherein alkyl is as defined above.
  • Cycloalkoxy means -O-cycloalkyl, wherein cycloalkyl is as defined above.
  • Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
  • Thioalkoxy is -S-alkyl, wherein alkyl is as defined above.
  • an aryl group designates a carbocyclic aromatic ring system such as phenyl, naphthyl (1 -naphthyl or 2-naphthyl) or fluorenyl.
  • the chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
  • Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydro- chloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like.
  • Such salts may be formed by procedures well known and described in the art.
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • onium salts of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention including compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
  • the chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the compounds of the present invention may exist in different stereoisomeric forms - including enantiomers, diastereomers and cis-trans-isomers.
  • the invention includes all such isomers and any mixtures thereof including racemic mixtures.
  • Optical active compounds can also be prepared from optical active starting materials.
  • the compounds of the invention may be used in their labelled or unlabelled form.
  • the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • the labelling will allow easy quantitative detection of said compound.
  • the labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.
  • the labelled isomer of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionuclide is preferably selected from 2 H (deuterium), 3 H (tritium), 13 C, 14 C, 131 I, 125 I, 123 I, and 18 F.
  • the physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.
  • PET Position Emission Tomography
  • SPECT Single Photon Imaging Computed Tomography
  • MRS Magnetic Resonance Spectroscopy
  • MRI Magnetic Resonance Imaging
  • CAT Computed Axial X-ray Tomography
  • the chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • Compounds of the invention may be tested for their ability to bind to the ⁇ , ⁇ , and K opioid receptors, e.g. such as described by Simonin F et al [Simonin F et al, MoI. Pharmacol., 46(6), 1015-21 , 1994], Simonin F et al [Simonin F et al, Proc. Natl. Acad. Sci. USA, 92(15), 7006-10, 1995], and Wang JB et al [Wang JB et al, FEBS Lett., 348(1), 75-9, 1994].
  • Compounds that bind to opiate receptors, in particular the ⁇ receptor, are likely to be useful in the treatment of pain, postoperative pain, chronic pain (such as cancer pain and neuropathic pain), pain during labour and delivery, migraine, drug addiction (such as heroin addiction and cocaine addiction), and alcoholism.
  • compounds that bind to opiate receptors are also likely to be useful in the treatment of irritable bowel syndrome, constipation, nausea, vomiting, and pruritic dermatoses (itching), such as allergic dermatitis and atopy.
  • Compounds that bind to opiate receptors have also been indicated in the treatment of eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, head trauma, diarrhoea, urinary incontinence and inflammatory reactions.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of a disease, disorder or condition responsive to modulation of the opioid receptors, in particular the ⁇ opioid receptor.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of pain, postoperative pain, chronic pain, cancer pain, neuropathic pain, pain during labour and delivery, migraine, drug addiction, heroin addiction, cocaine addiction, alcoholism, irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, allergic dermatitis, atopy, eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, head trauma, diarrhoea, urinary incontinence and inflammatory reactions.
  • the compounds of the invention are considered particularly useful for the treatment, prevention or alleviation of pain, postoperative pain, chronic pain, migraine, drug addiction, alcoholism, and irritable bowel syndrome.
  • the compounds of the invention also show activity as monoamine neurotransmitter re-uptake inhibitors.
  • the compounds of the invention may be tested for their ability to inhibit reuptake of the monoamines dopamine, noradrenaline and serotonin in synaptosomes e.g. such as described in WO 97/30997.
  • a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention.
  • a compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof.
  • forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations intended for conversion shortly before use to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
  • a therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity e.g. ED 50 and LD50, may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD50/ED50. Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day.
  • a satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o.
  • Preferred ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of the the opioid receptor, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • Example 1 The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed.
  • Example 1
  • Piperidine-1 ,4-dicarboxylic acid 1 -benzyl ester 4-ethyl ester (1 ) (165 g, 567. mmol) was dissolved in tetrahydrofuran (1500 ml_) and cooled to 0 0 C.
  • Lithium aluminium hydride (311 ml_, 1 M in THF) was added dropwise maintaining the temperature below 5°C.
  • the reaction mixture was stirred for one hour and aqueous sodium hydroxide (4 N) was added dropwise.
  • the mixture was filtered and the filtercake was washed with diethyl ether.
  • Example 10 ⁇ /-(4-Chloro-phenyl)-N-piperidin-4-ylmethyl-propionamide (1 Oa) 4- ⁇ [(4-Chloro-phenyl)-propionyl-amino]-methyl ⁇ -piperidine-1-carboxylic acid tert-butyl ester (9a) (8.80 g, 23.1 mmol) was dissolved in dichloromethane (150 ml_) and cooled to 0 0 C. Trifluoroacetic acid (50 ml_, 673 mmol) in dichlormethane (50 ml_) was added drop wise and the mixture was stirred for one hour at room temperature.
  • the crude product was purified by flash chromatography using dichloromethane/methanol as eluent to give ⁇ /-(4-chloro- phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide (3.0 g, 77%)
  • the product was dissolved in dichloromethane and fumaric acid dissolved in methanol was added and the mixture concentrated to give the product as the fumaric acid salt as a white solid. (3.48 g, 70%)
  • the gum-like solid was further purified by addition of water (20 ml) and was washed with diethylether (20 ml).
  • the aqueous mixture was made alkaline by adding aqueous sodium hydroxide (10 ml, 1 M) and was extracted with diethylether (2 x 20 ml).
  • Test Example Binding data The compounds have been tested in binding assays using human recombinant opiate ⁇ -, K- and ⁇ receptors.
  • the assays were conducted as previously described by Simonin F et al [Simonin F et al, MoI. Pharmacol., 46(6), 1015-21 , 1994], Simonin F et al [Simonin F et al, Proc. Natl. Acad. Sci. USA, 92(15), 7006-10, 1995], and Wang JB et al [Wang JB et al, FEBS Lett., 348(1 ), 75-9, 1994], The test results are presented in Table 1 below.
  • compound 12u was tested for functional activity in guinea pig ileum.
  • the assay was conducted as previously described by Maguire P et al [Maguire P et al, Eur. J. Pharmacol., 213(2), 219-25, 1992].
  • Compound 12u showed significant ⁇ agonist activity with an EC 5 O of 92 nM.
  • test values are given as IC 5 O (the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-DA, 3 H-NA, or ⁇ -5-HT by 50%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

This invention relates to novel 1-phenethylpiperidine derivatives of formuia (I) useful as opioid receptor ligands. More specifically, the invention provides compounds useful as μ opioid receptor ligands. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of pain, and to pharmaceutical compositions comprising the compounds of the invention.

Description

I-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS
TECHNICAL FIELD
This invention relates to novel 1-phenethylpiperidine derivatives useful as opioid receptor ligands. More specifically, the invention provides compounds useful as μ opioid receptor ligands.
In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of pain, and to pharmaceutical compositions comprising the compounds of the invention.
BACKGROUND ART
Numerous classes of opioid receptors exist. These classes differ in their affinity for various opioid ligands and in their cellular and organ distribution. Moreover, although the different classes are believed to serve different physiological functions, there is a substantial overlap of function, as well as distribution. Three different types of opioid receptors have been identified, the mu (μ), delta (δ) and kappa (K) opioid receptor. These three opioid receptor types are the sites of action of opioid ligands producing analgesic effects. However, the type of pain inhibited and the secondary functions vary with each receptor type. The μ receptor is generally regarded as primarily associated with pain relief, and drug or other chemical dependence, such as addiction or alcoholism. The δ receptor appears to deal with behavioural effects, although the δ and the K receptors may also mediate analgesia.
Each opioid receptor, when coupled with an opiate, causes a specific biological response unique to that type of receptor. When an opiate activates more than one receptor, the biological response for each receptor is affected, thereby producing side effects. The less specific and selective an opiate may be, the greater the chance of causing increased side effect by the administration of the opiate.
Whereas morphine, which is a strong opioid analgetic agent shows effectiveness against strong pain by acting on the μ opioid receptor (agonist activity), there is a problem that its side effects such as nausea and neurologic manifestation including hallucination and derangement. Moreover, morphine forms psychological dependence, causing serious problems. Other side effects reported are respiratory depression, tolerance, physical dependence capacity, and precipitated withdrawal syndrome, caused by non-specific interactions with central nervous receptors.
WO 03/004026 describes substituted 1-phenethylpiperidine compounds used as inter alia analgesics. SUMMARY OF THE INVENTION
It is an object of the invention to provide novel compounds which act on opiate 5 receptors.
A further object of the invention is the provision of compounds that substantially avoid the unwanted side effects associated with conventional peripherally acting analgesics.
It is a further object to provide compounds that bind selectively to the μ opioid o receptor.
A still further object is the provision of compounds that in addition show activity as monoamine neurotransmitter re-uptake inhibitors.
In its first aspect, the invention provides a compound of Formula I,
Figure imgf000003_0001
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof; wherein n, Ra, Rb and Rc are as defined below.
In its second aspect, the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, any of 0 its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent. In a further aspect, the invention provides the use of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the 5 treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the opioid receptor.
In a still further aspect, the invention relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal 0 body, including a human, which disorder, disease or condition is responsive to responsive to modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof. Other objects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.
DETAILED DISCLOSURE OF THE INVENTION
1 -phenethylpiperidine derivatives
In its first aspect, the invention provides a compound of Formula I,
Figure imgf000004_0001
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof; wherein n is 1 or 2; Ra represents hydrogen, alkyl or Rd; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; Rb represents Re or -CH2-Re; Rc represents Rf, -CH=CH-Rf or -CH=CH2; and Rd, Re and Rf independent of each other represent an aryl group; which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, sulfanyl, thioalkoxy,
-NR1R", -(C=O)NR1R" or -NR'(C=O)R"; wherein R' and R" independent of each other are hydrogen or alkyl.
In a further aspect, the invention provides a compound of Formula II,
Figure imgf000004_0002
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, wherein
Ra represents hydrogen, alkyl or Rd; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and Rb, Rc and Rd independent of each other represent an aryl group; which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, sulfanyl, thioalkoxy, -NR1R", -(C=O)NR1R" or -NR'(C=O)R"; wherein R' and R" independent of each other are hydrogen or alkyl.
In one embodiment of the compound of formula I, n is 1. In a second embodiment, n is 2.
In a further embodiment of the compound of formula I, Ra represents alkyl. In a special embodiment, Ra represents methyl or ethyl.
In a still further embodiment of the compound of formula I, Rb represents an optionally substituted aryl group, such as an optionally substituted phenyl. In a special embodiment, Rb represents phenyl. In a further embodiment, Rb represents halophenyl, such as fluorophenyl, chlorophenyl, 4-halophenyl or 3-halophenyl, in particular 4-chlorophenyl, 4-fluorophenyl or 3-fluorophenyl. In a further embodiment, Rb represents alkoxyphenyl, such as 4-alkoxyphenyl, 3-alkoxyphenyl or methoxyphenyl, in particular 4-methoxyphenyl or 3-methoxyphenyl. In a still further embodiment, Rb represents phenyl substituted with methylenedioxy, such as benzo[1 ,3]dioxol-5-yl.
In a further embodiment of the compound of formula I, Rb represents -CH2-R6. In a special embodiment, Rb represents benzyl.
In a still further embodiment of the compound of formula I, Rc represents an optionally substituted aryl group. In a special embodiment, Rc represents phenyl. In a further embodiment, Rc represents halophenyl, such as fluorophenyl, chlorophenyl, A- halophenyl or 3-halophenyl, in particular 4-chlorophenyl, 4-fluorophenyl or 3- fluorophenyl. In a still further embodiment, Rc represents alkoxyphenyl, such as A- alkoxyphenyl or methoxyphenyl, in particular 4-methoxyphenyl.
In a further embodiment of the compound of formula I, Rc represents -CH=CH- Rf. In a special embodiment, Rf represents phenyl. In a still further embodiment of the compound of formula I, Rc represents
-CH=CH2.
In a special embodiment the compound of the invention is
Λ/-(4-Chloro-phenyl)-Λ/-(1-phenethyl-piperidin-4-ylmethyl)-propionamide; 5 Λ/-(3-Methoxy-phenyl)-Λ/-(1-phenethyl-piperidin-4-ylmethyl)-propionamide;
Λ/-Benzo[1 ,3]dioxol-5-yl-Λ/-(1-phenethyl-piperidin-4-ylmethyl)-propionamide;
Λ/-Benzo[1 ,3]dioxol-5-yl-Λ/-{1-[2-(4-chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
Λ/-(4-Methoxy-phenyl)-Λ/-(1-phenethyl-piperidin-4-ylmethyl)-propionamide; o Λ/-{1 -[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-Λ/-(4-methoxy-phenyl)- propionamide;
Λ/-{1-[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-Λ/-(3-methoxy-phenyl)- propionamide ;
Λ/-(1-But-3-enyl-piperidin-4-ylmethyl)-Λ/-phenyl-propionamide; 5 Λ/-Phenyl-Λ/-[1 -((E)-3-phenyl-allyl)-piperidin-4-ylmethyl]-propionamide;
Λ/-{1-[2-(4-Fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}-Λ/-phenyl-propionamide;
Λ/-{1-[2-(3-Fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}-Λ/-phenyl-propionamide;
Λ/-(4-Fluoro-phenyl)-Λ/-(1-phenethyl-piperidin-4-ylmethyl)-propionamide;
Λ/-(4-Fluoro-phenyl)-Λ/-{1-[2-(3-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- 0 propionamide;
Λ/-(4-Fluoro-phenyl)-Λ/-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
Λ/-(4-Fluoro-phenyl)-Λ/-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide; 5 Λ/-(3-Fluoro-phenyl)-Λ/-(1-phenethyl-piperidin-4-ylmethyl)-propionamide;
Λ/-(3-Fluoro-phenyl)-Λ/-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
Λ/-(3-Fluoro-phenyl)-Λ/-{1-[2-(3-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide; 0 Λ/-Benzyl-Λ/-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide;
Λ/-(1-Phenethyl-piperidin-4-ylmethyl)-Λ/-phenyl-acetamide;
Λ/-(1-Phenethyl-piperidin-4-yl-methyl)-Λ/-phenyl-propionamide;
Λ/-(1-Benzyl-piperidin-4-ylmethyl)-Λ/-phenyl-propionamide;
Λ/-[1-(4-Chloro-benzyl)-piperidin-4-ylmethyl]-Λ/-phenyl-propionamide; 5 Λ/-{1-[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-Λ/-phenyl-propionamide; or a pharmaceutically acceptable salt thereof.
Any combination of two or more of the embodiments described herein is considered within the scope of the present invention. Definition of Substituents
In the context of this invention halo represents fluoro, chloro, bromo or iodo. In the context of this invention an alkyl group designates a univalent saturated, straight or branched hydrocarbon chain. The hydrocarbon chain preferably contains of from one to six carbon atoms (Ci-6-alkyl), including pentyl, isopentyl, neopentyl, tertiary pentyl, hexyl and isohexyl. In a preferred embodiment alkyl represents a Ci-4-alkyl group, including butyl, isobutyl, secondary butyl, and tertiary butyl. In another preferred embodiment of this invention alkyl represents a Ci-3-alkyl group, which may in particular be methyl, ethyl, propyl or isopropyl.
In the context of this invention an alkenyl group designates a carbon chain containing one or more double bonds, including di-enes, tri-enes and poly-enes. In a preferred embodiment the alkenyl group of the invention comprises of from two to six carbon atoms (C2-6-alkenyl), including at least one double bond. In a most preferred embodiment the alkenyl group of the invention is ethenyl; 1 - or 2-propenyl; 1 -, 2- or 3- butenyl, or 1 ,3-butadienyl; 1 -, 2-, 3-, 4- or 5-hexenyl, or 1 ,3-hexadienyl, or 1 ,3,5- hexatrienyl.
In the context of this invention an alkynyl group designates a carbon chain containing one or more triple bonds, including di-ynes, tri-ynes and poly-ynes. In a preferred embodiment the alkynyl group of the invention comprises of from two to six carbon atoms (C2-6-alkynyl), including at least one triple bond. In its most preferred embodiment the alkynyl group of the invention is ethynyl; 1 -, or 2-propynyl; 1 -, 2-, or 3- butynyl, or 1 ,3-butadiynyl; 1 -, 2-, 3-, 4-pentynyl, or 1 ,3-pentadiynyl; 1 -, 2-, 3-, A-, or 5- hexynyl, or 1 ,3-hexadiynyl or 1 ,3,5-hexatriynyl. In the context of this invention a cycloalkyl group designates a cyclic alkyl group, preferably containing of from three to seven carbon atoms (C3-7-cycloalkyl), including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Alkoxy is -O-alkyl, wherein alkyl is as defined above. Cycloalkoxy means -O-cycloalkyl, wherein cycloalkyl is as defined above. Cycloalkylalkyl means cycloalkyl as above and alkyl as above, meaning for example, cyclopropylmethyl.
Thioalkoxy is -S-alkyl, wherein alkyl is as defined above. In the context of this invention an aryl group designates a carbocyclic aromatic ring system such as phenyl, naphthyl (1 -naphthyl or 2-naphthyl) or fluorenyl.
Pharmaceutically Acceptable Salts
The chemical compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the chemical compound of the invention.
Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydro- chloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by procedures well known and described in the art.
Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.
Examples of pharmaceutically acceptable cationic salts of a chemical compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a chemical compound of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art.
In the context of this invention the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts. Preferred "onium salts" include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
Examples of pre- or prodrug forms of the chemical compound of the invention include examples of suitable prodrugs of the substances according to the invention including compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
The chemical compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention. Steric Isomers
It will be appreciated by those skilled in the art that the compounds of the present invention may exist in different stereoisomeric forms - including enantiomers, diastereomers and cis-trans-isomers. The invention includes all such isomers and any mixtures thereof including racemic mixtures.
Methods for the resolvation of optical isomers, known to those skilled in the art may be used, and will be apparent to the average worker skilled in the art. Such methods include those discussed by J. Jaques, A. Collet, and S. Wilen in "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, New York (1981 ).
Optical active compounds can also be prepared from optical active starting materials.
Labelled Compounds The compounds of the invention may be used in their labelled or unlabelled form. In the context of this invention the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. The labelling will allow easy quantitative detection of said compound. The labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.
The labelled isomer of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionuclide is preferably selected from 2H (deuterium), 3H (tritium), 13C, 14C, 131 I, 125I, 123I, and 18F.
The physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.
Methods of Preparation
The chemical compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals. Also one compound of the invention can be converted to another compound of the invention using conventional methods.
The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
Biological Activity
Compounds of the invention may be tested for their ability to bind to the μ, δ, and K opioid receptors, e.g. such as described by Simonin F et al [Simonin F et al, MoI. Pharmacol., 46(6), 1015-21 , 1994], Simonin F et al [Simonin F et al, Proc. Natl. Acad. Sci. USA, 92(15), 7006-10, 1995], and Wang JB et al [Wang JB et al, FEBS Lett., 348(1), 75-9, 1994].
Compounds that bind to opiate receptors, in particular the μ receptor, are likely to be useful in the treatment of pain, postoperative pain, chronic pain (such as cancer pain and neuropathic pain), pain during labour and delivery, migraine, drug addiction (such as heroin addiction and cocaine addiction), and alcoholism.
Furthermore, compounds that bind to opiate receptors are also likely to be useful in the treatment of irritable bowel syndrome, constipation, nausea, vomiting, and pruritic dermatoses (itching), such as allergic dermatitis and atopy. Compounds that bind to opiate receptors have also been indicated in the treatment of eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, head trauma, diarrhoea, urinary incontinence and inflammatory reactions.
Thus in further aspect, the compounds of the invention are considered useful for the treatment, prevention or alleviation of a disease, disorder or condition responsive to modulation of the opioid receptors, in particular the μ opioid receptor.
In a special embodiment, the compounds of the invention are considered useful for the treatment, prevention or alleviation of pain, postoperative pain, chronic pain, cancer pain, neuropathic pain, pain during labour and delivery, migraine, drug addiction, heroin addiction, cocaine addiction, alcoholism, irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, allergic dermatitis, atopy, eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, head trauma, diarrhoea, urinary incontinence and inflammatory reactions.
In a further embodiment, the compounds of the invention are considered particularly useful for the treatment, prevention or alleviation of pain, postoperative pain, chronic pain, migraine, drug addiction, alcoholism, and irritable bowel syndrome. In a still further embodiment, the compounds of the invention also show activity as monoamine neurotransmitter re-uptake inhibitors. The compounds of the invention may be tested for their ability to inhibit reuptake of the monoamines dopamine, noradrenaline and serotonin in synaptosomes e.g. such as described in WO 97/30997. It is at present contemplated that a suitable dosage of the active pharmaceutical ingredient (API) is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
Pharmaceutical Compositions
In another aspect the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention.
While a compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
In a preferred embodiment, the invention provides pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof. Pharmaceutical compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems. Suitable examples of sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules. The chemical compound of the invention, together with a conventional adjuvant, carrier, or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof. Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
The chemical compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a chemical compound of the invention or a pharmaceutically acceptable salt of a chemical compound of the invention.
For preparing pharmaceutical compositions from a chemical compound of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glyceride or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate. Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions. For example, parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
The chemical compound according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
Also included are solid form preparations, intended for conversion shortly before use to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. In addition to the active component such preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
For topical administration to the epidermis the chemical compound of the invention may be formulated as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
Compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The compositions may be provided in single or multi-dose form.
Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by provision of a metered valve. Alternatively the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). Conveniently the powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
When desired, compositions adapted to give sustained release of the active ingredient may be employed.
The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA). A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity, e.g. ED50 and LD50, may be determined by standard pharmacological procedures in cell cultures or experimental animals. The dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD50/ED50. Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
The active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 μg/kg i.v. and 1 μg/kg p.o. The upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Preferred ranges are from about 0.1 μg/kg to about 10 mg/kg/day i.v., and from about 1 μg/kg to about 100 mg/kg/day p.o.
Methods of Therapy
In another aspect the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to modulation of the the opioid receptor, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of the invention, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
It is at present contemplated that suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
EXAMPLES
The invention is further illustrated with reference to the following examples, which are not intended to be in any way limiting to the scope of the invention as claimed. Example 1
Piperidine-1 ,4-dicarboxylic acid 1 -benzyl ester 4-ethyl ester (1)
Ethyl 4-piperidinecarboxylate (99.48 g, 632,78 mmol) and pyridine (56.8 g, 696 mmol) were dissolved in dichloromethane (800 ml_) and cooled to 00C. Benzyl chloroformate (88.1 ml_, 601 mmol) was added dropwise and the reaction mixture was allowed to reach room temperature overnight. The reaction was quenched with aqueous hydrochloric acid (1 M), extracted with dichloromethane, washed with brine, dried over sodium sulphate, filtered and concentrated to give piperidine-1 ,4-dicarboxylic acid 1- benzyl ester 4-ethyl ester (165 g, 89%) as a yellow oil.
Example 2
4-Hydroxymethyl-piperidine-1-carboxylic acid benzyl ester (2)
Piperidine-1 ,4-dicarboxylic acid 1 -benzyl ester 4-ethyl ester (1 ) (165 g, 567. mmol) was dissolved in tetrahydrofuran (1500 ml_) and cooled to 00C. Lithium aluminium hydride (311 ml_, 1 M in THF) was added dropwise maintaining the temperature below 5°C. The reaction mixture was stirred for one hour and aqueous sodium hydroxide (4 N) was added dropwise. The mixture was filtered and the filtercake was washed with diethyl ether. The organic layer was concentrated and dissolved in ethyl acetate, washed with water and brine, dried over sodium sulphate, filtered and concentrated to give 4-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester (120 g, 85%) as a yellow oil.
Example 3
4-Formyl-piperidine-1-carboxylic acid benzyl ester (3) Oxalyl chloride (59.1 ml_, 674 mmol) was dissolved in dichloromethane (500 ml_) and cooled to -78°C. Dimethylsulfoxide (68.3 ml_, 963 mmol) was added and the mixture was stirred for 15 min. 4-Hydroxymethyl-piperidine-1-carboxylic acid benzyl ester (2) (120 g, 481 mmol) dissolved in dichloromethane (500 ml_) was added. The mixture was allowed to warm to -55°C for 15 min. The mixture was again cooled to -78°C and triethylamine (205 ml_, 1443 mmol) in dichloromethane (250 ml_) was added. The suspension was allowed to warm to room temperature and quenched with glacial acetic acid (100 ml_). The solution was washed with water and the aqueous phase extracted with dichloromethane (2 x 200 ml_). The combined organic layers were washed with brine, dried over sodium sulphate, filtered and concentrated to give 4- formyl-piperidine-1-carboxylic acid benzyl ester (119 g, 100%). Example 4
4-[(3-Fluoro-phenylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester (4)
4-Formyl-piperidine-1-carboxylic acid benzyl ester (3) (2.00 g, 8.09 mmol) and 3- fluoroaniline (1.16 ml_, 12.1 mmol) was dissolved in 1 ,2-dichloroethane (40 ml_). Sodium sulphate (5.74 g, 40.4 mmol) and sodium triacetoxyborohydride (2.74 g, 12.9 mmol) were added and the reaction was stirred at room temperature overnight. Aqueous sodium hydroxide was added carefully and the reaction mixture was stirred for an additional half hour followed by extraction with dichloromethane. The organic phases were washed with brine, dried over sodium sulphate, filtered and concentrated. The crude product was purified by flash chromatography using ethyl acetate/heptane as eluent to give 4-[(3-fluoro-phenylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester (380 mg, 14%)
Example 5 4-{[(3-Fluoro-phenyl)-propionyl-amino]-methyl}-piperidine-1-carboxylic acid benzyl ester (5)
4-[(3-Fluoro-phenylamino)-methyl]-piperidine-1-carboxylic acid benzyl ester (4) (1.12 g, 3.27 mmol) and triethyl amine (0.70 ml_, 4.90 mmol) were dissolved in dichloromethane (50 ml_) and the mixture was cooled to 00C. Propionyl chloride (0.38 ml_, 4.25 mmol) was added and the reaction was stirred at room temperature overnight. Aqueous sodium hydrogen carbonate was added and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with brine, dried over sodium sulphate, filtered and concentrated. The crude product was purified by flash chromatography using ethyl acetate/heptane as eluent to give 4-{[(3- fluoro-phenyl)-propionyl-amino]-methyl}-piperidine-1-carboxylic acid benzyl ester (800 mg, 61 %).
Example 6 N-(3-Fluoro-phenyl)-N-piperidin-4-ylmethyl-propionamide (6) 4-{[(3-Fluoro-phenyl)-propionyl-amino]-methyl}-piperidine-1-carboxylic acid benzyl ester (5) (800 mg, 2.01 mmol) was dissolved in ethanol (30 ml_) and palladium (10% on activated carbon) was added. The reaction mixture was stirred under a hydrogen atmosphere for 3 hours. The mixture was filtered through a pad of kieselguhr and the solution concentrated in vacuo to give N-(3-fluoro-phenyl)-N-piperidin-4-ylmethyl- propionamide (480 mg, 90%) as a colorless oil. Example 7
4-[(Benzyl-propionyl-amino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester
(7)
4-(Propionylamino-methyl)-piperidine-1-carboxylic acid te/t-butyl ester (9b) (530 mg, 1.96 mmol) was dissolved in tetrahydrofuran (10 ml_) and cooled to 00C. Sodium hydride (86 mg, 2.16 mmol) was added portion wise and the reaction mixture was stirred for 45 min at 00C. Benzyl chloride (0.24 ml_, 2.35 mmol) was added and the reaction mixture was heated to reflux over night. Aqueous sodium hydrogen carbonate was added and the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulphate filtered and concentrated in vacuo to give 4-[(benzyl-propionyl-amino)-methyl]-piperidine-1- carboxylic acid tert-butyl ester (900 mg, 100%) as a yellow oil.
Example 8 ^[(^Chloro-phenylaminoJ-methyll-piperidine-i-carboxylic acid tert-butyl ester (8a)
4-Aminomethyl-piperidine-1-carboxylic acid te/t-butyl ester (10.0 g, 46.7 mmol), A- bromochlorobenzene (10.7 g, 56.0 mmol) and sodium te/t-butoxide (6.73 g, 70.0 mmol) were dissolved in toluene (150 ml_). Argon was bubbled through. 4,5- Bis(diphenylphosphino)-9,9-dimethylxanthene (Xanthphos) (810 mg, 1.40 mmol) and ths(dibenzylidineacetonedipalladium (Pd2(dba)3) (427 mg, 0.47 mmol) were added and the mixture was stirred at 110°C for 3 hours. Aqueous sodium hydrogen carbonate was added and the mixture was filtrated. The organic layer was washed with brine, died over sodium sulphate in combination with activated charcoal. The mixture was filtered through a pad of kieselguhr and concentrated to give the crude product as an orange sticky oil. 4-[(4-Chloro-phenylamino)-methyl]-piperidine-1-carboxylic acid tert- butyl ester (9.1 g, 60%) was crystallized from ethyl acetate/heptane as a white solid.
Compounds 8b-8f were prepared in parallel with compound 8a from 4-aminomethyl- piperidine-1-carboxylic acid te/t-butyl ester and the various aryl halides as shown in the table below.
Figure imgf000018_0001
Figure imgf000019_0002
Example 9
4-{[(4-Chloro-phenyl)-propionyl-amino]-methyl}-piperidine-1 -carboxylic acid tert- butyl ester (9a)
4-[(4-Chloro-phenylamino)-methyl]-piperidine-1 -carboxylic acid te/t-butyl ester (8.8 g, 27.1 mmol) and triethylamine (4.04 ml_, 28.4 mmol) were dissolved in dichloromethane (120 ml_) and cooled to 0 0C. Propionyl chloride (2.53 ml_, 28.4 mmol) in dichloromethane (20 ml_) was added dropwise and the reaction mixture was stirred at room temperature for 2 hours. Water was added and the organic layer was washed with aqueous sodium hydrogen carbonate, water and brine. The organic layer was dried over sodium sulphate, filtered and concentrated to give 4-{[(4-chloro-phenyl)- propionyl-amino]-methyl}-piperidine-1 -carboxylic acid tert-butyl ester (12 g, 100%) as a yellow oil.
Compounds 9b-9g were prepared in parallel with compound 9a as shown in the table below.
Figure imgf000019_0001
Figure imgf000020_0001
^[(Acetyl-phenyl-aminoJ-methyll-piperidine-i-carboxylic acid tert-butyl ester (9h) Was prepared according to Example 9 from 8b and acetyl chloride instead of propionyl chloride.
Example 10 Λ/-(4-Chloro-phenyl)-N-piperidin-4-ylmethyl-propionamide (1 Oa) 4-{[(4-Chloro-phenyl)-propionyl-amino]-methyl}-piperidine-1-carboxylic acid tert-butyl ester (9a) (8.80 g, 23.1 mmol) was dissolved in dichloromethane (150 ml_) and cooled to 00C. Trifluoroacetic acid (50 ml_, 673 mmol) in dichlormethane (50 ml_) was added drop wise and the mixture was stirred for one hour at room temperature. The reaction mixture was concentrated and triturated with toluene, ethylacetate and diethylether. The resulting solid was filtered and washed with diethyl ether to give N-(4-chloro- phenyl)-Λ/-piperidin-4-ylmethyl-propionamide (9.2 g, 100%) as the trifluroacetic acid salt.
Compounds 10b-IOg were prepared in parallel with compound 10a as shown in the table below.
Figure imgf000021_0001
10b-IOg
Figure imgf000021_0002
Example 11 5 Methanesulfonic acid 2-(3-fluoro-phenyl)-ethyl ester (11)
3-Fluorophenethyl alcohol (0.89 ml_, 7.13 ml_) and pyridine (1.16 ml_, 14.3 mmol) were dissolved in dichloromethane (10 ml_). Methanesulfonyl chloride (0.67 ml_, 8.56 ml_) was added and the reaction mixture was stirred at room temperature over night. The reaction mixture was poured into ice water and extracted with dichloromethane. The 10 combined organic phases were washed with hydrochloric acid (1 M in water) and brine, dried over sodium sulphate, filtered and concentrated. The crude product was used without further purification.
Example 12
15 Λ/-(4-Chloro-phenyl)-N-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide f umaric acid salt (12a)
Λ/-(4-Chloro-phenyl)-N-piperidin-4-ylmethyl-propionamide (4.0 g, 10.1 mmol) and potassium carbonate (3.64 g, 21.3 mmol) were dissolved in 2-butanone (60 ml_). (2- Bromoethyl)benzene (1.46 ml_, 10.6 mmol) was added and the mixture was stirred at 20 500C over night. Aqueous sodium hydrogen carbonate was added and the aqueous phase was extracted with dichloromethane. The combined organic phases were dried over sodium sulphate, filtered and concentrated. The crude product was purified by flash chromatography using dichloromethane/methanol as eluent to give Λ/-(4-chloro- phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide (3.0 g, 77%) The product was dissolved in dichloromethane and fumaric acid dissolved in methanol was added and the mixture concentrated to give the product as the fumaric acid salt as a white solid. (3.48 g, 70%)
Mp = 165-166°C LC-ESI-HRMS of [M+H]+ shows 385.2048 Da. CaIc. 385.204666 Da, dev. 0.3 ppm
Compounds 12b-12t were prepared in parallel with compound 12a as shown in the table below.
Figure imgf000022_0001
12b-12s 12t
Figure imgf000022_0002
Figure imgf000023_0001
N-(3-Methoxy-phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide fumaric acid salt (12b)
Mp.139-1410C LC-ESI-HRMS of [M+H]+ shows 381.2538 Da. CaIc. 381.254203 Da, dev. -1.1 ppm
N-Benzo[1 ,3]dioxol-5-yl-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide fumaric acid salt (12c)
Mp. = 85-88°C. LC-ESI-HRMS of [M+H]+ shows 395.2325 Da. CaIc. 395.233468 Da, dev. -2.4 ppm N-Benzo[1 ,3]dioxol-5-yl-N-{1-[2-(4-chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide fumaric acid salt (12d)
Mp = 125-128°C LC-ESI-HRMS of [M+H]+ shows 429.1958 Da. CaIc. 429.194496 Da, dev. 3 ppm
N-(4-Methoxy-phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide fumaric acid salt (12e)
Mp = 114-116°C LC-ESI-HRMS of [M+H]+ shows 381.2539 Da. CaIc. 381.254203 Da, dev. -0.8 ppm
N-{1-[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-(4-methoxy-phenyl)- propionamide fumaric acid salt (12f)
LC-ESI-HRMS of [M+H]+ shows 415.2156 Da. CaIc. 415.215231 Da, dev. 0.9 ppm
N-{1 -[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-(3-methoxy-phenyl)- propionamide fumaric acid salt (12g)
Mp. = 136-139°C LC-ESI-HRMS of [M+H]+ shows 415.2166 Da. CaIc. 415.215231 Da, dev. 3.3 ppm
N-(1-But-3-enyl-piperidin-4-ylmethyl)-N-phenyl-propionamide fumaric acid salt (12h)
Mp. = 113-116°C LC-ESI-HRMS of [M+H]+ shows 301.2268 Da. CaIc. 301.227988 Da, dev. -3.9 ppm
N-Phenyl-N-[1 -((E)-3-phenyl-allyl)-piperidin-4-ylmethyl]-propionamide fumaric acid salt (12i)
Mp. = 38-410C LC-ESI-HRMS of [M+H]+ shows 363.2436 Da. CaIc. 363.243638 Da, dev. -0.1 ppm
N-{1-[2-(4-Fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-phenyl-propionamide fumaric acid salt (12j)
Mp. = 141-143°C LC-ESI-HRMS of [M+H]+ shows 369.2356 Da. CaIc. 369.234216 Da, dev. 3.7 ppm
N-{1-[2-(3-Fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-phenyl-propionamide fumaric acid salt (12k)
Mp. = 142-145°C LC-ESI-HRMS of [M+H]+ shows 369.2339 Da. CaIc. 369.234216 Da, dev. -0.9 ppm N-(4-Fluoro-phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide fumaric acid salt (121)
Mp. = 126-128°C LC-ESI-HRMS of [M+H]+ shows 369.233 Da. CaIc. 369.234216 Da, dev. -3.3 ppm
N-(4-Fluoro-phenyl)-N-{1-[2-(3-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide fumaric acid salt (12m)
Mp. = 130-1330C LC-ESI-HRMS of [M+H]+ shows 387.2245 Da. CaIc. 387.224794 Da, dev. -0.8 ppm
N-(4-Fluoro-phenyl)-N-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide fumaric acid salt (12n)
Mp. = 132-134°C LC-ESI-HRMS of [M+H]+ shows 399.2453 Da. CaIc. 399.244781 Da, dev. 1.3 ppm
N-(4-Fluoro-phenyl)-N-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide fumaric acid salt (12o)
Mp. = 145-147°C LC-ESI-HRMS of [M+H]+ shows 387.225 Da. CaIc. 387.224794 Da, dev. 0.5 ppm
N-(3-Fluoro-phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide fumaric acid salt (12p)
Mp. = 58-60 LC-ESI-HRMS of [M+H]+ shows 369.2329 Da. CaIc. 369.234216 Da, dev. -3.6 ppm
N-(3-Fluoro-phenyl)-N-{1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide fumaric acid salt (12q)
Mp. = 65-67°C LC-ESI-HRMS of [M+H]+ shows 387.2256 Da. CaIc. 387.224794 Da, dev. 2.1 ppm
N-(3-Fluoro-phenyl)-N-{1-[2-(3-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide fumaric acid salt (12r)
Mp. = 142-145°C. LC-ESI-HRMS of [M+H]+ shows 387.2233 Da. CaIc. 387.224794 Da, dev. -3.9 ppm
N-Benzyl-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide fumaric acid salt (12s)
Mp.= 46-49°C LC-ESI-HRMS of [M+H]+ shows 365.2591 Da. CaIc. 365.259288 Da, dev. -0.5 ppm N-(1-Phenethyl-piperidin-4-ylmethyl)-N-phenyl-acetamide fumaric acid salt (12t)
Mp. = 207-2080C LC-ESI-HRMS of [M+H]+ shows 337.2284 Da. CaIc. 337.227988 Da, dev. 1.2 ppm
Λ/-(1 -Phenethyl-piperidin-4-yl-methyl)-Λ/-phenyl-propionamide hydrochloric acid salt (12u)
A mixture of Λ/-phenyl-Λ/-piperidin-4-yl-methyl-propionamide (0.30 g, 1.22 mmol), 2- phenethyl bromide (0.27 g, 1.46 mmol), sodium hydride, 60% in mineral oil (0.06 g, 1.5 mmol) and tetrahydrofuran (15 ml) was stirred at 15 h at 6O0C followed by 70 h at room temperature. Water (20 ml) was added and the mixture was extracted with diethylether (2 x 30 ml). The diethylether phase was washed with water (20 ml). The hydrochloride was precipitated by addition of hydrogen chloride in ethanol. The gum-like solid was further purified by addition of water (20 ml) and was washed with diethylether (20 ml). The aqueous mixture was made alkaline by adding aqueous sodium hydroxide (10 ml, 1 M) and was extracted with diethylether (2 x 20 ml). The hydrochloride was was precipitated by addition of hydrogen chloride in ethanol. Yield 0.27 g (63%). Mp = 1520C.
Compounds 11 v-11 y were prepared in parallel with compound 11 u as shown in the table below.
Figure imgf000026_0001
12v-12y
Figure imgf000026_0002
N-(1-Benzyl-piperidin-4-ylmethyl)-N-phenyl-propionamide fumaric acid salt (12v)
Mp. = 58-600C LC-ESI-HRMS of [M+H]+ shows 337.2267 Da. CaIc. 337.227988 Da, dev. -3.8 ppm
N-[1 -(^Chloro-benzyO-piperidin-^ylmethyll-N-phenyl-propionamide fumaric acid salt (12x)
Mp. = 148-1500C LC-ESI-HRMS of [M+H]+ shows 371.1897 Da. CaIc. 371.189016 Da, dev. 1.8 ppm
N-{1-[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-phenyl-propionamide fumaric acid salt (12y)
Mp. = 157-158°C LC-ESI-HRMS of [M+H]+ shows 385.2028 Da. CaIc. 385.204666 Da, dev. -4.8 ppm
Example 13 Λ/-Phenyl-Λ/-piperidin-4-yl-methyl-propionamide (13)
A mixture of 4-[(phenyl-propionyl-amino)-methyl]-piperidine-1-carboxylic acid tert-butyl ester (4.85 g, 14 mmol) and hydrogen chloride in acetic acid (20 ml, 4 M) was stirred at room temperature for 5 h. The solvent was evaporated. Aqueous sodium hydroxide (20 ml, 1 M) was added and the mixture was extracted with ethylacetate (3 x 30 ml) followed by dichloromethane (30 ml). The crude mixture was purified by silica gel chromatography, using a solvent mixture of dichloromethane, methanol and concentrated aqueous ammonia (6:1 +1 %) as eluent. Yield 0.30 g (9%) as colourless oil.
Example 14
4-[(Phenyl-propionyl-amino)-methyl]-piperidine-1-carboxylic acid ferf-butyl ester
(14) A mixture of 4-phenylaminomethyl-piperidine-1-carboxylic acid te/t-butyl ester (4.07 g, 14 mmol), propionic anhydride (2.19 g, 16.8 mmol), triethylamine (1.7 g, 16.8 mmol) and tetrahydrofuran (80 ml) was stirred at reflux for 15 h. Water (100 ml) was added and the mixture was extracted with diethylether (2 x 60 ml). The diethylether phase was washed with water (2 x 50 ml). Yield 5.05 g (100%).
Example 15
4-Phenylaminomethyl-piperidine-1-carboxylic acid ferf-butyl ester (15)
A mixture of 4-aminomethyl-piperidine-1-carboxylic acid te/t-butyl ester (10.13 g, 47.3 mmol), bromobenzene (8.2 g, 52 mmol), palladacycle (0.30 g, 0.32 mmol), potassium tert-butoxide (1 1 .1 g, 99. 3 mmol) and dioxane (50 ml) was stirred at 100 0C for 15 h Water (100 ml) was added followed by extraction with diethylether (3 x 50 ml). The diethylether phase was washed with water (2 x 50 ml). The mixture was dried and evaporated. The crude mixture was purified by silica gel chromatography, using a solvent mixture of dichloromethane, methanol and concentrated aqueous ammonia (6:1 +1 %) as eluent. Yield 6.18 g (45%).
Test Example Binding data The compounds have been tested in binding assays using human recombinant opiate δ-, K- and μ receptors. The assays were conducted as previously described by Simonin F et al [Simonin F et al, MoI. Pharmacol., 46(6), 1015-21 , 1994], Simonin F et al [Simonin F et al, Proc. Natl. Acad. Sci. USA, 92(15), 7006-10, 1995], and Wang JB et al [Wang JB et al, FEBS Lett., 348(1 ), 75-9, 1994], The test results are presented in Table 1 below.
Table 1
Figure imgf000028_0001
Furthermore, one compound, compound 12u, was tested for functional activity in guinea pig ileum. The assay was conducted as previously described by Maguire P et al [Maguire P et al, Eur. J. Pharmacol., 213(2), 219-25, 1992]. Compound 12u showed significant μ agonist activity with an EC5O of 92 nM.
In vitro inhibition activity
A number of compounds were tested for their ability to inhibit the reuptake of the monoamine neurotransmitters dopamine (DA) noradrenaline (NA) and serotonine (5- HT) in synaptosomes as described in WO 97/16451.
The test values are given as IC5O (the concentration (μM) of the test substance which inhibits the specific binding of 3H-DA, 3H-NA, or Η-5-HT by 50%).
Test results obtained by testing selected compounds of the present invention appear from the below table: Table 2
Figure imgf000029_0001

Claims

1. A compound of Formula I:
Figure imgf000030_0001
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof; wherein n is 1 or 2;
Ra represents hydrogen, alkyl or Rd; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; Rb represents Re or -CH2-Re;
Rc represents Rf, -CH=CH-Rf or -CH=CH2; and
Rd, Re and Rf independent of each other represent an aryl group; which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, sulfanyl, thioalkoxy, -NR'R", -(C=O)NR1R" or -NR'(C=O)R"; wherein R' and R" independent of each other are hydrogen or alkyl.
2. The compound according to claim 1 being a compound of formula II:
Figure imgf000030_0002
any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof; wherein Ra represents hydrogen, alkyl or Rd; which alkyl is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, nitro, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl and alkynyl; and Rb, Rc and Rd independent of each other represent an aryl group; which aryl group is optionally substituted with one or more substituents independently selected from the group consisting of: halo, trifluoromethyl, trifluoromethoxy, cyano, nitro, hydroxy, alkoxy, cycloalkoxy, alkoxyalkyl, cycloalkoxyalkyl, methylenedioxy, ethylenedioxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, sulfanyl, thioalkoxy, -NR'R", -(C=O)NR1R" or -NR'(C=O)R"; wherein R' and R" independent of each other are hydrogen or alkyl.
3. The compound according to claims 1 or 2, wherein Ra represents alkyl.
4. The compound according to any one of claims 1-3, wherein Rb represents an optionally substituted phenyl.
5. The compound according to any one of claims 1-4, wherein Rc represents an optionally substituted phenyl.
6. A compound of claim 1 which is
Λ/-(4-Chloro-phenyl)-Λ/-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide; Λ/-(3-Methoxy-phenyl)-Λ/-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide; N-Benzo[1 ,3]dioxol-5-yl-Λ/-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide; N-Benzo[1 ,3]dioxol-5-yl-Λ/-{1 -[2-(4-chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
N-(4-Methoxy-phenyl)-Λ/-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide;
N-{1 -[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-(4-methoxy-phenyl)- propionamide; N-{1 -[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-(3-methoxy-phenyl)- propionamide ;
N-(1 -But-3-enyl-piperidin-4-ylmethyl)-N-phenyl-propionamide;
N-Phenyl-N-[1-((E)-3-phenyl-allyl)-piperidin-4-ylmethyl]-propionamide;
N-{1 -[2-(4-Fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-phenyl-propionamide; N-{1 -[2-(3-Fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-phenyl-propionamide;
N-(4-Fluoro-phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide;
N-(4-Fluoro-phenyl)-N-{1 -[2-(3-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide; N-(4-Fluoro-phenyl)-N-{1 -[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
N-(4-Fluoro-phenyl)-N-{1 -[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
N-(3-Fluoro-phenyl)-N-(1-phenethyl-piperidin-4-ylmethyl)-propionamide; N-(3-Fluoro-phenyl)-N-{1 -[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
N-(3-Fluoro-phenyl)-N-{1 -[2-(3-fluoro-phenyl)-ethyl]-piperidin-4-ylmethyl}- propionamide;
N-Benzyl-N-(1 -phenethyl-piperidin-4-ylmethyl)-propionamide; N-(1 -Phenethyl-piperidin-4-ylmethyl)-N-phenyl-acetamide;
Λ/-(1 -Phenethyl-piperidin-4-yl-methyl)-Λ/-phenyl-propionamide;
N-(1 -Benzyl-piperidin-4-ylmethyl)-N-phenyl-propionamide;
N-[1 -(4-Chloro-benzyl)-piperidin-4-ylmethyl]-N-phenyl-propionamide;
N-{1 -[2-(4-Chloro-phenyl)-ethyl]-piperidin-4-ylmethyl}-N-phenyl-propionamide; or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of any one of claims 1 -6, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
8. The use of a compound according to any one of claims 1 -6, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the opioid receptor.
9. The use according to claim 8, wherein the disease, disorder or condition responsive to modulation of the opioid receptor is pain, postoperative pain, chronic pain, cancer pain, neuropathic pain, pain during labour and delivery, migraine, drug addiction, heroin addiction, cocaine addiction, alcoholism, irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, allergic dermatitis, atopy, eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, head trauma, diarrhoea, urinary incontinence and inflammatory reactions.
10. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to any one of the claims 1-6, any of its isomers or any mixture of its isomers, or a pharmaceutically acceptable salt thereof.
PCT/EP2007/051400 2006-02-17 2007-02-13 1-phenethylpiperidine derivatives and their use as opioid receptor ligands WO2007093603A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT07726356T ATE466841T1 (en) 2006-02-17 2007-02-13 1-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS
DE602007006280T DE602007006280D1 (en) 2006-02-17 2007-02-13 1-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS
US12/161,309 US20100234427A1 (en) 2006-02-17 2007-02-13 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
CA002641913A CA2641913A1 (en) 2006-02-17 2007-02-13 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
EP07726356A EP1987001B1 (en) 2006-02-17 2007-02-13 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
JP2008554765A JP2009526815A (en) 2006-02-17 2007-02-13 1-phenethylpiperidine derivatives and their use as opioid receptor ligands

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200600232 2006-02-17
DKPA200600232 2006-02-17
US77466806P 2006-02-21 2006-02-21
US60/774,668 2006-02-21

Publications (1)

Publication Number Publication Date
WO2007093603A1 true WO2007093603A1 (en) 2007-08-23

Family

ID=37963788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/051400 WO2007093603A1 (en) 2006-02-17 2007-02-13 1-phenethylpiperidine derivatives and their use as opioid receptor ligands

Country Status (7)

Country Link
US (1) US20100234427A1 (en)
EP (1) EP1987001B1 (en)
JP (1) JP2009526815A (en)
AT (1) ATE466841T1 (en)
CA (1) CA2641913A1 (en)
DE (1) DE602007006280D1 (en)
WO (1) WO2007093603A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077584A1 (en) * 2007-12-19 2009-06-25 Neurosearch A/S N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
WO2009077574A1 (en) * 2007-12-19 2009-06-25 Neurosearch A/S N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
WO2017049177A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US10703712B2 (en) 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016215A2 (en) * 2007-08-02 2009-02-05 Neurosearch A/S N-aryl-n-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
BR112019018774A2 (en) * 2017-03-12 2020-04-07 Wang Xiaodong compound having a structure according to formula i, pharmaceutically acceptable salt, pharmaceutical composition, method for preventing or treating a disease or condition and method for immunomodulation, inhibiting or preventing rejection of organ or skin grafts or treating tumors or cancer
US11584765B2 (en) 2017-03-12 2023-02-21 Ecstasy LLC Polycyclic amines as sigma receptor modulators
AU2021300217A1 (en) 2020-07-01 2023-02-02 Ecstasy, LLC Polycyclic amines for opioid receptor modulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457686A1 (en) * 1990-05-18 1991-11-21 Adir Et Compagnie Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them
WO2001081308A2 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
WO2004035541A1 (en) * 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214055A (en) * 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
DE10132746A1 (en) * 2001-07-05 2003-02-06 Gruenenthal Gmbh Substituted 1-phenethylpiperidine compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457686A1 (en) * 1990-05-18 1991-11-21 Adir Et Compagnie Novel aminopiperidine, aminopyrrolidine and aminoperhydroazepine derivatives, process for their preparation and pharmaceutical compositions containing them
WO2001081308A2 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
WO2004035541A1 (en) * 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077584A1 (en) * 2007-12-19 2009-06-25 Neurosearch A/S N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
WO2009077574A1 (en) * 2007-12-19 2009-06-25 Neurosearch A/S N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
WO2017049177A1 (en) * 2015-09-16 2017-03-23 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US10377717B2 (en) 2015-09-16 2019-08-13 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US10626081B2 (en) 2015-09-16 2020-04-21 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US10703712B2 (en) 2015-09-16 2020-07-07 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
US11214538B2 (en) 2015-09-16 2022-01-04 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof

Also Published As

Publication number Publication date
EP1987001A1 (en) 2008-11-05
ATE466841T1 (en) 2010-05-15
DE602007006280D1 (en) 2010-06-17
EP1987001B1 (en) 2010-05-05
JP2009526815A (en) 2009-07-23
CA2641913A1 (en) 2007-08-23
US20100234427A1 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
EP1987001B1 (en) 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
US7915419B2 (en) Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110046180A1 (en) N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
US7560562B2 (en) Piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7973082B2 (en) Substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
EP1899303B1 (en) Novel 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20100331367A1 (en) N-aryl-n-piperidin-4-yl-propionamide derivatives and their use as opioid receptor ligands
EP2245011A1 (en) Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20090023772A1 (en) Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors
US20110046179A1 (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8093388B2 (en) 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1899301B1 (en) Novel 3-aza-spiro[5.5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2008009832A (en) 1-phenethylpiperidine derivatives and their use as opioid receptor ligands
US20100298380A1 (en) N-aryl-n-piperidin-4-ylmethyl-amide derivatives and thier use as monoamine neurotransmitter re-uptake inhibitors
NZ538514A (en) Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007726356

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/009832

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008554765

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2641913

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE